GISAID, Nextstrain, Illumina
Among all the nose swabs that have ever come up positive for covid-19 over the course of the pandemic, about two in a hundred have been sent for extra analysis in a gene sequencing machine. The objective: to create a fresh map of the SARS-CoV-2 virus’s genome—all 30,000 or so letters—and see what’s changed.
Such genetic surveillance has allowed scientists to quickly spot and warn about new variants like alpha, delta, and mostly recently omicron. It’s an unprecedented effort that’s turned SARS-CoV-2 into history’s most sequenced organism—blasting past the flu, HIV, or even our own human genome. Open databases now display more than 7 million maps of the germ’s genes.
Omicron is the most dramatic evolution yet. A lab in South Africa first sent up a warning flare in November after its sequencers spotted a virus genome with more than 50 mutations. Almost instantly, computers in Seattle, Boston, and London were using the data to spit out predictions: omicron was trouble, a variant likely to evade antibodies.
One thing the sequencers can’t yet tell us is how, exactly, SARS-CoV-2 will evolve next. That’s why some say we should be tracking the germ even more closely. The majority of sequences are being generated in places like the UK, the US, and Denmark. But the virus can still evolve, unwitnessed, in regions without the capacity to sequence. Luckily, the quick work in South Africa to spot omicron and track its spread gave the world an early warning.
As part of our 10 Breakthrough Technologies series, meet the scientist who warned the world about omicron.
CORRECTION: GISAID is an organization that promotes rapid sharing of flu and coronavirus genetic data and Nextstrain is a project developing software for analyzing such data. An earlier version of this article incorrectly referred to both as databases.
These scientists used CRISPR to put an alligator gene into catfish
The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.
Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.
CRISPR for high cholesterol: 10 Breakthrough Technologies 2023
New forms of the gene-editing tool could enable treatments for common diseases.
This biotech startup says mice live longer after genetic reprogramming
The result is a widely anticipated landmark for rejuvenation technology.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.